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Asthma and allergies represent two of the most prevalent chronic illnesses in the 
US, affecting 23 million individuals and 40-50 million individuals, respectively (Pleis, 
Ward, & Lucas, 2010; NIAID, 2003).  Although these diseases are often recognized as 
non-life threatening (Rolland, 1987), both asthma and allergies have significant 
implications for the social, emotional, occupational, and physical functioning of 
individuals with these diseases.  Currently, much of the research regarding each of these 
diseases focuses primarily on younger children (Akinbami, Moorman, Garbe, & Sondik, 
2009; Teufel et al, 1999), and the research regarding allergies focuses on specific 
subgroups (i.e. food allergies) and not the broader disease itself (Teufel, et al., 1999).  
Furthermore, very little research has examined the specific psychosocial functioning of 
adolescents and young adults (AYAs) with chronic illnesses such as asthma (Perez-
Yarza, 1996).  
At the same time, research has shown that both children and adults with asthma 
and with allergies have pejorative psychosocial outcomes in comparison to healthy 
controls (e.g., Adams et al, 2004; Cuffel et al, 1999; Gillaspy, Hoff, Mullins, Van Pelt, & 
Chaney, 2002).  Specifically, researchers have found that children and adults with asthma 
have increased prevalence rates of depressive and anxiety symptoms (e.g., Adams et al, 
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2004; Gillaspy et al, 2002), and that children and adults with asthma have lower health-
related quality of life (HRQOL) than healthy controls (e.g., Adams et al, 2004; Fedele et 
al, 2009).  Similarly, researchers have found that children and adults with allergies have 
increased depressive and anxiety symptoms in comparison to healthy controls (e.g., 
Cuffel et al, 1999; Kagan et al, 1991).  As well, that children and adults with allergies 
have lower HRQOL than health controls (e.g., Metzler et al, 1997).  Noticeably, research 
examining psychosocial functioning in individuals with allergies is quite limited.   
The current study expanded upon the existing literature by examining the rates of 
psychological distress, specifically, depressive and anxiety symptoms, as well as the 
emotional and physical quality of life between AYAs with allergies, AYAs with asthma, 
and healthy AYAs.  The following aims guided this research: 
Aim 1: To examine the rates of psychological distress, specifically depressive 
symptoms and anxiety symptoms, between AYAs with allergies, with asthma, and 
healthy controls.   
Aim 2
 With regard to Aim 1, it was hypothesized that AYAs with asthma and AYAs 
with allergies would have higher levels of anxiety and depressive symptoms than healthy 
AYAs, while there would be no difference between anxiety and depressive symptoms 
between AYAs with asthma and AYAs with allergies.   
: To examine emotional and physical quality of life between AYAs with 
allergies, with asthma, and healthy controls.   
 With regard to Aim 2, it was hypothesized that AYAs with asthma and AYAs 
with allergies would report lower physical and emotional quality of life than healthy 
    
3 
 
AYAs, while there would be no difference between physical and emotional quality of life 
between AYAs with asthma and AYAs with allergies.  






REVIEW OF LITERATURE  
Chapter Overview 
This chapter examines the literature pertinent for the current study, which is 
divided into five sections.  The first section focuses on a description of asthma, including 
information on the etiology, prevalence, mortality, morbidity, healthcare utilization, and 
treatment of the disease.  The second section focuses on the psychosocial outcomes of 
individuals with asthma, specifically anxiety, depression, and health-related quality of 
life.  The third section focuses on a description of allergies including information on the 
etiology, prevalence, mortality, morbidity, healthcare utilization, and treatment of the 
disease.  The next section focuses on the psychosocial outcomes of individuals with 
allergies, specifically anxiety, depression, and health-related quality of life.  The fifth 
section provides a brief overview of Rolland’s family systems illness model and its 
applicability to understanding individuals with asthma and allergies.  
Asthma: Description of the Disease 
Asthma is characterized by chronic inflammation, narrowing, and hypersensitivity 
of the bronchial tubes (Adams, 2007). The narrowing of the bronchial tubes prevents
Nature and Etiology of Asthma 
    
5 
 
airflow to the lungs; however, with treatment this narrowing can usually be reversed 
(NIH, 2007). The hypersensitivity or hyperirritability of the bronchial tubes can influence 
and trigger asthma attacks in individuals (Adams, 2007).  During an asthma attack, 
inflammation and narrowing of the bronchial tubes occurs, as well as excessive secretion 
of mucus, both of which prevent airflow and without treatment, suffocation can occur 
(Adams, 2007). 
Overall, the etiology and subsequent development of asthma can be attributed to 
the interaction of genetics, environment, immunity, and allergies (NIH, 2007).  To date, 
over ten different genes have been described as influencing asthma; however, because of 
the complexity of mechanisms involved, little is understood about the true influence of 
genetics on the disease (Adams, 2007).  Researchers have also suggested that imbalanced 
levels of immune lymphocytes, Th1 and Th2 cytokine, specifically the overexpression of 
Th2, may support the development of asthma in individuals (NIH, 2007).   Allergic 
diseases also influence the development of asthma, as allergic reactions can cause 
inflammation in the lungs and obstruct airflow (Adams, 2007).  Environmental factors 
such as, exposure to smoke, diet, occupation, and air pollution have also been shown to 
increase the risk of developing asthma (NIH, 2007).  To better understand the disease, 
asthma is categorized as being extrinsic or intrinsic.  Extrinsic asthma develops mostly 
during childhood and is triggered by allergens and environmental factors, while intrinsic 
asthma develops mostly during adulthood and is often triggered by immunity factors and 
infections (Adams, 2007).  This classification is relatively antiquated; however, it can 
help individuals with asthma and health care professionals determine the optimal 
treatment that fits the manifestation of the disease (Adams, 2007).   
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Across the United States, asthma is extremely common, affecting approximately 
23 million individuals (Pleis, Ward, & Lucas, 2010).  Asthma prevalence rates can vary 
as a function of age, sex, race, and social-economic status (SES). Although prevalence 
rates for children are higher than adults, approximately 16 million adults currently have a 
diagnosis of asthma (Moorman et al, 2007).   In adults with asthma, females (8.1%) have 
higher rates than males (6.2%), African Americans (9.2%) have slightly higher rates than 
Caucasians (6.9%), and individuals below the poverty level (10.3%) have higher rates 
than individuals above the poverty line (7.9%; Moorman et al, 2007; Pleis & Lethbridge-
Cejku, 2007). Comparatively, asthma is the most common chronic illness of children, 
with a prevalence rate of 7.1 million children (10.0%) currently having asthma (Bloom, 
Cohen, & Freeman, 2010).  In contrast with adults, boys (17%) are more likely than girls 
(10%) to have ever had an asthma diagnosis (Bloom et al, 2010) and American Indian 
and African American children are more likely to have asthma than Caucasian children 
(Akinbamia et al, 2009).  In total, approximately 12 million individuals reported asthma 
attacks in 2006, with 7.5 million (3.6%) occurring in adults and 4.1 million (5.6%) 
occurring in children (Moorman et al, 2007).   
Prevalence, Mortality, Morbidity 
The mortality rate for asthma is relatively low.  Over a three year period (2001-
2003), 4210 deaths occurred due to asthma, with less than 5% occurring in children 
(Moorman et al, 2007).  The majority of the deaths occurred in females (64%) and in 
adults over the age of 65 (50%; Moorman et al, 2007).   Although the mortality of asthma 
is relatively low, for both children and adults, the morbidity of the disease indicates the 
need to further understand the nature of asthma and the impact it has on individuals.   
    
7 
 
In 2008, over 18 billion dollars was spent on expenses related to the treatment of 
asthma in adults (Sullivan et al., 2011).  Each adult with asthma spent approximately 
$2000 on medical expenses specifically due to the disease (Sullivan et al., 2011).  Of this 
total, 28% was spent on prescription medicines, 19% on inpatient hospitalization, and 
19% on home health care expenditures (Sullivan, 2011).  Adults with asthma also had 
increased emergency room visits and over twice the number of prescription medications 
than individuals without asthma (Sullivan et al, 2011).  Furthermore, the health care 
utilization for children increased the total amount of money spent related to the disease, 
as approximately 8 billion dollars was spent on expenses associated with asthma in 
children in 2006 (Soni, 2009a).  
Health Care Utilization  
However, the utilization of health care resources is not equitably divided across 
individuals with the disease.  Although asthma has higher prevalence rates among older 
children (11-17 years old), younger children (0-11 years old) demonstrate evidence of 
higher utilization of overall health care resources (Akinbamia et al, 2009).  For children 
and adults, asthma ranks as the second and fourth most costly chronic illness 
respectively, thus the level of health care utilization is quite high for individuals with 
asthma (Soni, 2009a; Soni, 2009b). 
 The treatment of asthma usually involves several medications to control and 
prevent symptoms; as such, there are both quick and long term relief medications (Weiss 
et al, 2006).   Quick relief medications are intended to relieve asthma attacks while, long 
term relief medications are used to prevent and reduce the severity of asthma attacks and 
Treatment of Asthma 
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symptoms (Weiss et al, 2006).  Across all of the treatment options, there are large 
individual differences for the effectiveness of medications, and often tailored treatment 
plans are created to manage symptoms (Douglass, 2002).   
Quick relief medications are most often used in those individuals with mild 
asthma and are combined with preventative medications for individuals with moderate to 
severe asthma.  The most common quick relief medications are bronchodilators or beta2-
agonists (Weiss et al, 2006), with short-acting beta2
In contrast, long term relief medications are used to help prevent and control 
asthma systems in individuals with moderate to severe asthma, and as such, should be 
used regularly (NIH, 2007).  There are several long term medications (e.g., 
corticosteroids, cromolyn sodium, nedocromil sodium, and immunomodulators); 
however, the most effective medication, for most individuals, is inhaled corticosteroids 
(NIH, 2007).  Inhaled steroids work directly on the inflamed airways and have less side 
effects than other medications; however, oral steroids can be stronger for individuals with 
severe symptoms, but these medications have increased detrimental effects (e.g., hair 
growth, weight gain) (Adams, 2007).  In general, long term relief medications are 
preventative and need to be used regularly and consistently to provide protection from 
asthma attacks (Adams, 2007).   
-agonists demonstrating the most 
effective treatment across the majority of individuals (NIH, 2007).  These medications 
work by activating mechanisms in the smooth muscle that will allow the airways to relax 
(Weiss et al, 2006).  As quick relievers, these medications are mostly inhaled and should 
be used for acute attacks, not for continued management of the disease (NIH, 2007).    
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With the use of treatment plans, individuals with asthma can ideally be able to 
control and manage their symptoms.  It is important for individuals with asthma to 
understand the environmental triggers (e.g., animals, dust, pollen, smoke) that may 
influence their asthma and to adhere to the medication regimen to best control and 
prevent asthma attacks (Adams, 2007).  The following section examines the psychosocial 
functioning of individuals with asthma. 
Asthma: Psychosocial Outcomes 
Depression is defined as a negative mood state characterized by a cluster of 
symptoms, including feelings of sadness or emptiness, loss of interest in activities, loss of 
energy, feelings of worthlessness as well as behavioral symptoms such as weight change, 
difficulty sleeping, and increased movement (DSM-IV TR, 2000).  For a number of 
years, researchers have sought to examine the relationship between asthma and 
depression and/or depressive symptomatology.   
Asthma and Depression 
Although the current literature is mixed, research has indicated an increased 
likelihood of depressive symptoms in children with asthma (Bennett, 1994; Bloomberg & 
Chen, 2005; Gillaspy et al, 2002; Padur et al, 1995) and in adults with asthma (Adams et 
al, 2004; McCauley, Katon, Russo, Richardson, & Lozano, 2007).  Research has also 
demonstrated that children with asthma have significantly more depressive symptoms 
compared to children with other chronic illnesses, and also to children with no chronic 
illness (Padur et al, 1995).  Similarly, in a study of high-risk adolescents, Gillaspy and 
colleagues (2002) found that adolescents with asthma had significantly increased 
depressive symptomatology compared to adolescents without asthma.  Further research 
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with adult populations has again corroborated the findings with children and adolescents, 
with Adams and colleagues (2004) finding that adults with asthma evidence higher rates 
of depressive symptoms than adults without asthma.  However, other researchers have 
found contradictory results, such that children and adolescents with asthma are no 
different from healthy children with regard to depressive symptomatology (Vila, Nollet-
Clemencon, de Blic, Mouren-Simeoni, & Scheinmann, 2000).   
Across the research literature, there is some variability as to whether the severity 
of asthma impacts the prevalence of depression or depressive symptoms in individuals 
with asthma.  McCauley and colleagues (2007) found that depressive symptoms were 
related to impairment in psychosocial and asthma-related functioning in adolescents with 
asthma, but the severity of asthma was not related to the depressive or anxious symptoms.   
In contrast, other researchers have found that the severity of asthma was significantly 
related to the increased prevalence of depression or anxiety disorders in children and 
adolescents with asthma (Blackman & Gurka, 2007), while other researchers have linked 
depressive symptoms with perceived high-severity asthma, rather than objectified high-
severity asthma (Janson-Bjerklie, Ferketich, Benner, & Becker, 1992).  Overall, the 
research examining the illness severity and the influence on depressive symptoms is 
variable, perhaps due to differing methods of measuring the severity of asthma symptoms 
or the use of objective versus subjective reporting of severity in individuals with asthma.   
Depressive symptoms may influence the treatment and management of asthma 
symptoms and healthcare utilization in individuals with the disease.  In this vein, 
researchers have found that in adults with asthma, the presence of depressive symptoms 
reduces the compliance and control of the treatment for the disease (Bosley, Fosbury, & 
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Cochrane, 1995; Strine et al, 2008) and that children with asthma and a comorbid 
depressive disorder have increased healthcare utilization compared to children with 
asthma but without depressive disorder (Richardson et al, 2006).  Additionally, 
researchers have found that depressive symptoms may influence the cognitive 
functioning of individuals with asthma (DiMatteo et al, 2000; Opolski & Wilson, 2005).  
However, other researchers have concluded that the depressive symptoms may not 
account for the total cognitive impairment observed in individuals with asthma (Chaney 
et al/, 1999).  Thus, depressive symptomatology may negatively influence the 
management and control of the symptoms, as well as healthcare utilization in individuals 
with asthma. 
Overall, the current research suggests that individuals with asthma have increased 
prevalence of depression and depressive symptoms compared to individuals without 
asthma, and these depressive symptoms may increase difficulties adhering to treatment 
plans for control of the disease.  As well, the severity of the disease may influence the 
prevalence of depression or depressive symptoms.  In the following section, the literature 
examining the prevalence of anxiety symptoms and disorders within individuals with 
asthma is discussed.   
Anxiety disorders can cause individuals to be fearful and uncertain in specific 
situations, when exposed to specific stimuli, or without triggers (DSM-IV TR, 2000).  
The symptoms can range from psychological symptoms such as, fear or worry, to somatic 
symptoms such as, racing heart or sweating; overall, these symptoms can be debilitating 
and fearful for individuals (DSM-IV TR, 2000).  Similar to depression, researchers have 
Asthma and Anxiety 
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sought to elucidate the relationship between anxiety and asthma.  Collectively, the current 
literature indicates an increased likelihood of anxious symptoms in children with asthma 
(Bennett, 1994; Bloomberg & Chen, 2005; Katon et al, 2007; Gillaspy et al, 2002) and in 
adults with asthma (Adams et al, 2004; Fernandes et al, 2010; McCauley et al, 2007).  
Specifically, researchers have examined the prevalence of anxiety and depression in 
youth with and without asthma and found that youth with asthma have an increased 
likelihood of having either an anxiety or depressive disorder than healthy youth (Katon et 
al., 2007).  Although researchers have shown elevated rates of anxiety disorders in 
children with asthma, it appears that these rates can vary (Ortega, Huertas, Canino, 
Ramirez, & Rubio-Stipec, 2002; Wamboldt et al, 1996; Vila et al, 2000).  Katon and 
colleagues (2004) concluded that approximately a third of children with asthma meet 
criteria for an anxiety disorder, with adults showing lower prevalence rates of anxiety 
disorder, comparatively.  Adams and colleagues (2004) found that adults with asthma, 
similarly to children with asthma, have more anxious symptoms than healthy controls.   
The presence of anxiety symptomatology may also influence aspects such as 
healthcare utilization in individuals with asthma.  Researchers have found that the 
prevalence of anxiety symptoms in adults with asthma has also been associated with 
decreased control of asthma symptoms and increased health care utilization (Fernandes et 
al, 2010; Strine, Mokdad, Balluz, Berry, & Gonzalez, 2008), such that individuals with 
higher levels of anxiety symptoms have increased urgent and routine medical visits due 
to asthma related health concerns (Fernandes et al, 2010).  Thus, anxiety symptoms may 
increase healthcare utilization in individuals with asthma.   
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Importantly, research is inconsistent regarding whether the prevalence of anxiety 
disorders can influence the severity of symptoms in individuals with asthma.  McCauley 
and colleagues (2007) found that anxiety and depressive symptoms were not associated 
with asthma severity as measured by markers of high medical risk including, an oral 
prescription for asthma symptoms, more than one emergency room visit due to asthma 
related problems, or four or more physician visits for asthma management.  In contrast, 
other researchers measured severity by the number of asthma attacks, medication usage, 
and hospitalizations due to asthma and found that asthma severity does influences 
depressive and anxious symptoms in individuals with asthma (Silverglade, Tosi, Wise, & 
D’Costa, 1994).  Differing methodology for measuring severity may explain some of the 
variability researchers have found regarding the influence of asthma severity on anxiety 
and depressive symptoms in individuals with asthma. 
Similar to the depression literature, research suggests that individuals with asthma 
have an increased likelihood of anxiety symptoms or disorders.  In the following section, 
the literature examining quality of life in individuals with asthma is reviewed.   
To understand broader impact of asthma on individuals daily functioning, quality 
of life (QOL) has been examined.  QOL is a global construct that examines individuals’ 
expectations and goals in relation to culture and belief systems (WHO, 1993).  The 
construct of health-related quality of life (HRQOL) further examines how illnesses and 
diseases influence the emotional, physical, and social functioning of individuals (Ware & 
Sherbourne, 1992).   
Asthma and Quality of Life 
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 In this vein, researchers have examined HRQOL in individuals with asthma 
compared to individuals without asthma.  Researchers demonstrated that adolescents and 
adults with asthma had significantly lower HRQOL scores when compared to adolescents 
and adults without asthma (Adams et al, 2004; Fedele et al, 2009; Schmier, Chan, & 
Leidy, 1998).  However, within the research examining HRQOL, not all researchers 
confirm deficits across all domains of HRQOL (Adams et al, 2004; Fedele et al, 2009).  
Additionally, researchers have found that anxiety and depressive symptoms contributed 
to HRQOL (Hommell et al, 2002), and that individuals with asthma who had a lifetime 
diagnosis of depression or anxiety had lower HRQOL scores than individuals with 
asthma without a diagnosis of depression or anxiety symptoms (Stine et al, 2008).    
In addition to decreased HRQOL, both children and adults with asthma appear to 
have specific impairment in academic or occupational functioning due to asthma, 
domains of functioning typically conceptualized as comprising HRQOL.  Blackman and 
Gurka (2007) found that children with asthma missed over 10 more days of school than 
children without asthma.  As well, the self-reported severity of symptoms impacted 
absenteeism as a greater percentage of children with severe asthma missed over 10 days 
in the last year than those children with mild and moderate asthma (Blackman & Gurka, 
2007).  Carpentier and colleagues (2007) found that college students with asthma missed 
more days of school or work than college students without asthma, further corroborating 
these results.  For adults and children in the United States, approximately 14.41 million 
workdays and 3.68 million school days are missed due to asthma each year (Barnett & 
Nurmagambetov, 2011).  This data clearly shows the interference of asthma on academic, 
occupational, and daily functioning. 
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 Overall, researchers have found diminished levels of HRQOL in children and 
adults with asthma; although, there is some variability across the individual HRQOL 
domains affected.  The burden of this disease in individuals can also be seen by the 
impact on occupational and academic absenteeism.   
           In the next section, we examine the nature of allergies, specifically, the etiology, 
prevalence, mortality, morbidity, healthcare utilization, and treatment.       
Allergy: Description of the Disease 
An allergic response occurs when an individual’s immune system reacts to an 
innocuous substance (e.g., animals, food, environment, medicines, and pollens) and 
produces an antibody immunoglobulin E (IgE; National Institute of Allergy and 
Infectious Diseases [NIAID], 2003).    Every substance has a unique IgE antibody and 
when the antibody comes into contact with the corresponding substance, chemicals such 
as histamine, cytokines, and leukotrienes are released (NIAID, 2003).  These chemicals 
initiate body systems to respond, causing symptoms including hives, atopic dermatitis, 
airway constriction, sneezing, and nasal congestion (NIAID, 2003).  The symptoms are 
often multi-systematic, affecting respiratory (i.e., nose, throat, chest, eyes, and ears), 
gastrointestinal (i.e., mouth, stomach), genitourinary, and skin systems (Zellerbach, 
2000).   
Nature and Etiology of Allergies 
Allergies can be categorized by several specific diseases including allergic 
rhinitis, food allergy, drug allergy, and contact dermatitis (Zellerbach, 2000).  Allergic 
rhinitis is the most common allergic disease and is characterized by the typically 
experienced symptoms of nasal congestion, sneezing, and headaches (Zellerbach, 2000).  
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The common triggers for allergic rhinitis are household dust, pollen, molds, and animal 
dander (Zellerbach, 2000).  Additionally, allergic rhinitis can be categorized as seasonal, 
perennial, or episodic (McCrory, et al., 2003; Zellerbach, 2000).  Seasonal allergies occur 
during distinctive seasons; triggers could include pollens, grasses, or fertilizers 
(Zellerbach, 2000). Perennial allergies occur year-round and can often be triggered by 
molds, dust, or animal dander, while episodic allergies occur randomly (e.g., insect 
stings) (Zellerbach, 2000). Food allergies occur when a food substance triggers the 
allergic response; common food triggers include peanuts, tree nuts, shellfish, sugar, milk, 
eggs, and wheat (Neugut, Ghatak, & Miller, 2001; Zellerbach, 2000).  Drug allergies 
occur when a medication incites the allergic response; common drug allergies are to 
antibiotics and dye used for medical imaging (Neugut, et al., 2001).  Allergic contact 
dermatitis is where the skin develops a rash because of contact with a substance; common 
substances that trigger contact dermatitis include latex, beauty products, and the Rhus 
plant family (Zellerbach, 2000).    
 
Across the United States, allergic diseases are extremely common, affecting 
between 40 and 50 million individuals (NIAID, 2003).  The prevalence of allergies can 
vary on age, sex, and race; with prevalence rates for children being higher than adults, 
females being higher than males, and Asians being lower than other races (Pleis & 
Lethbridge-Cejku, 2007; Pleis, Ward, & Lucas, 2010).     
Prevalence, Mortality, Morbidity 
Allergic rhinitis is the most common allergic disease, affecting 10 to 30 percent of 
the adult population and up to 40 percent of the pediatric population (McCrory, et al., 
2003).  In 2009, the prevalence rate for adults with allergic rhinitis was 17.7 million 
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adults (7.8%; Pleis et al., 2010).  Comparatively, 7.2 million children (9.8%) have 
allergic rhinitis, 3.8 million children (5.2%) have food allergies, and 8.9 million children 
(12%) have skin allergies (Bloom, Cohen, & Freeman, 2010).  Because of the 
considerable prevalence rate of allergic diseases, allergies constitute the sixth largest 
chronic illness in the United States (McCrory, et al., 2003).   
The mortality rate for allergies is not collected by the federal government in 
national health studies; however, there are some mortality estimates for specific allergic 
diseases. In the United States each year, food allergies cause approximately 100 deaths, 
drug allergies cause approximately 1300 deaths, and insect stings cause approximately 
40-100 deaths (Neugut, et al., 2001).   Together, these allergic diseases kill approximately 
.002% of the population in the United States each year (Neugut, et al., 2001).  Although 
the mortality of allergic diseases is relatively low, the prevalence of allergies and 
associated morbidity indicates the need to further understand the nature of these diseases 
and the subsequent impact they have on individuals.   
In 2005, over 11.2 billion dollars was spent on expenses related to the treatment 
of allergic rhinitis, excluding money spent on over-the-counter medications (Soni, 2008).  
Of this total, over half (58.7%) was spent on prescription medicines and approximately a 
third (35.9%) was spent on out-patient doctor’s visits (Soni, 2008).  In addition to 
prescription medicines, over-the-counter medications are used by over half of allergy 
sufferers, and thus the true cost of allergic rhinitis is even higher (HealthStar 
Communications, Inc., Schulman, Ronca, & Bucuvalas, Inc., 2006).  There are also 
indirect costs of allergic rhinitis such as emergency room visits; although, the incidence 
Health Care Utilization  
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rates for allergic disease emergency room visits are quite low with approximately 7900 
total visits in 1995 (Klein & Yocum, 1995).  These costs demonstrate mostly how allergic 
rhinitis impacts health care utilization; however, additional allergic diseases differ in 
treatments and add to the utilization of health care. 
 The treatment of allergies depends on the specific disease (e.g., allergic rhinitis, 
contact dermatitis); however, there are three main avenues for treatment: environmental 
control, immunotherapy, and pharmacotherapy (Berger, 2003; Zellerbach, 2000).  
Environmental control occurs when the substance that causes the reaction is avoided 
(NIAID, 2003).  This treatment method works best for allergens that can readily be 
avoided, such as specific foods, medications, animals, and plants.  However, it can be 
hard for some individuals with allergic rhinitis to determine the specific trigger and 
eliminate the substance which may be commonly occurring such as pollen, mold, and 
dust (Naclerio, 1991; Stempel & Woolf, 2002).  To limit exposure to pollens and mold, 
the individual with these allergies can wear a mask or reduce outdoor activities when the 
pollen levels are high (NIAID, 2003).   
Treatment of Allergies 
 Immunotherapy attempts to reduce allergic reactions in individuals by receiving 
injections of the substance to which they are allergic (NIAID, 2003; Zellerbach, 2000).  
The injections occur at least weekly at the beginning of treatment and gradually decrease 
over a three to five year period (NIAID, 2003; Zellberbach, 2000).  The purpose of the 
injections is to increase the antibody IgG (a protective antibody), which will build up 
tolerance and reduce the reaction when the substance is presented (Naclerio, 1991; 
Zellerbach, 2000).  This treatment method is most effective with allergies that do not 
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respond to medication or that involve substances that cannot be avoided (Berger, 2003; 
Naclerio, 1991).  One concern with this treatment is the necessary adherence to the 
injection protocol over an extended period of time (Berger, 2003).   
 Pharmacotherapy is the use of medications to control the symptoms associated 
with allergies.  These medications can include antihistamines, decongestants, and 
corticosteroids (Berger, 2003; Stempel & Woolf, 2002).  Antihistamines counter the body 
system’s response to the allergen, preventing the symptoms from occurring (NIAID, 
2003).  Antihistamines have advanced considerably from the first formulas, and now are 
used to control symptoms for 24 hours and prevent drowsiness (Stempel & Woolf, 2002).  
Decongestants, which limit and prevent blood flow to the nasal passages, are often 
combined with antihistamines to provide relief to congestion and nasal symptoms of 
allergy sufferers (Naclerio, 1991; Stempel & Woolf, 2002).  Both antihistamines and 
decongestants are mostly used with individuals with allergic rhinitis; however, 
corticosteroids can also be used for individuals with allergic rhinitis and contact 
dermatitis (Zellerbach, 2000).  Corticosteroids can take several forms, including nasal 
sprays, topical creams, and pills; each method preferable depending on the allergic 
disease (Zellerbach, 2000).  The treatment of allergies is a complex process that can 
involve multiple attempts to find the combination of medication or avoidance of triggers 
to control symptoms.  The next section examines the psychosocial functioning in 
individuals with allergies.   
Allergy: Psychosocial Outcomes 
Allergies and Depression 
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In adults, depression is a negative mood state characterized by a cluster of 
symptoms including feelings of sadness or emptiness, loss of interest in activities, loss of 
energy, feelings of worthlessness as well as behavioral symptoms such as weight change, 
difficulty sleeping, and increased movement (DSM-IV TR, 2000).  Although the current 
literature is limited, research has indicated an increased likelihood of depressive 
symptoms in children with allergies (Bell, 1992; Patten et al., 2009) and in adults with 
allergies (e.g. Bell, 1991; Marshall et al., 2002).   
Specifically, higher rates of depressive symptoms have been found in both 
children and adults with allergies compared to healthy controls (Bell, 1992).  Further, 
Patten and Williams (2007) found higher prevalence of self-reported depressive 
symptoms in adults with allergies with both food and non-food allergies showing 
significant differences from the healthy controls. Such findings suggest that psychosocial 
concerns may exist for individuals who experience multiple types of allergies.  Cuffel and 
colleagues (1999) also found that individuals with allergies had higher rates of depression 
than individuals without allergies. They examined  individuals who had depression as 
defined by an ICD-code diagnosis of major depression, dysthymia, or a diagnosis of brief 
depressive reaction, or, had filled two or more prescription claims for an anti-depressant, 
and, whether or not these individuals also had been diagnosed with allergies as defined 
by the individual filling two or more prescriptions for allergy medications.  By examining 
the patient records the researchers were able to objectively discern the presence of 
depression or allergies.  Interestingly, Goodwin and colleagues (2006) found that 
depression was associated with increased incidence of allergies in adult females, but did 
not replicate this finding in males.   
    
21 
 
 Researchers have further examined the rate of depressive symptomatology within 
individuals with seasonal allergies in relation to the pollen season.  Marshall and 
colleagues (2002) found that during the pollen season, adults with allergies had higher 
levels of fatigue, lower motivation levels, and lower positive affect than they had during 
the non-pollen season. Related, researchers have demonstrated increased suicidal ideation 
in adults with self-reported seasonal allergies compared to healthy adults (Messias et al., 
2010).  Interestingly, Marshall (1993) looked at problem-solving, psychomotor speed, 
attention, memory, and mood in individuals with allergies compared to individuals with 
no chronic illnesses, testing participants in and out of pollen season.  Their findings 
suggest that the individuals with allergies demonstrated decreased abilities in memory, 
problem solving, psychomotor speed as well as lower mood levels during pollen season 
compared to their performance out of the pollen season (Marshall, 1993).   
          Overall, the current research suggests that individuals with allergies are indeed 
experiencing higher levels of depressive symptoms compared to individuals without 
allergies, and that individuals with allergies have increases in depressive symptomatology 
during the pollen season.  In the following section, the literature examining the 
prevalence of anxiety symptomatology in individuals with allergies is reviewed.   
For a number of years, researchers have sought to examine the prevalence of 
anxiety symptoms in individuals with allergies.  Researchers tend to examine the 
construct of anxiety differently; however, many characterize anxiety as an affective state 
involving excessive worries and behavioral symptoms such as difficultly sleeping, 
tension, restless, or fatigue (Buske-Kirschbaum et al., 2008; DSM IV TR, 2000), while 
Allergies and Anxiety 
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others look at specific anxiety disorders (Kovalenko et al, 2001; Patten & Williams, 
2007).  Some of the first studies discerning the relationship between anxiety and allergies 
examined shyness, and found that individuals with high levels of shyness and 
introversion had an increased precedence of hay fever than less shy individuals (Bell, 
1990).  Continuing from this research, other researchers looked at anxiety and its 
relationship to allergies (e.g., Buske-Kirschbaum et al., 2008; Cuffel et al., 1999; Kagan 
et al., 1991).   
The literature suggests that both children with allergies (Kagan et al, 1991) and 
adults with allergies (Buske-Kirschbaum et al., 2008) exhibit higher levels of anxiety and 
anxiety symptoms than healthy controls.  Buske-Kirschbaum and colleagues (2008) 
found that adults with two specific allergy subtypes (i.e., atopic dermatitis and seasonal 
allergic rhinitis) had significantly higher levels of anxiety and stress vulnerability 
compared to healthy controls.  As well, Cuffel and colleagues (1999) examined the 
relationship between anxiety and allergies and found that in both children and adults the 
prevalence rates of an anxiety disorder (an ICD-9 code of panic disorder, generalized 
anxiety disorder, simple phobia, social phobia, obsessive-compulsive disorder, 
posttraumatic stress disorder, agoraphobia, or other phobia) was higher than healthy 
controls.  Additional research has examined the relationship between allergic diseases 
and specific anxiety disorder. In this vein, Kovalenko and colleagues (2001) looked at the 
prevalence of anxiety disorders in children with allergies and found an association 
between children with allergies and panic disorder, such that children with allergies had 
higher rates of panic disorder.  Similarly, Patten and Williams (2007) found that adults 
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with non-food allergies have higher prevalence of panic disorder and social phobia than 
healthy controls.   
Although adult research is sparse, researchers have begun to elucidate the 
relationship between allergies and anxiety disorders.  This literature indeed suggests that 
children and adults with allergies have an increased prevalence for anxiety disorders and 
anxiety symptoms comparative to healthy controls.  In the following section, the 
literature on HRQOL in individuals with allergies is reviewed.  
To better understand how allergies impact individual’s daily lives, QOL has also 
been examined.  As noted previously, QOL is a broad construct examining an 
individual’s goals, expectations, and position in life in relation to culture and beliefs 
(WHO, 1993).  HRQOL is a further extension of QOL, examining the influence of 
illnesses and diseases as they affect the emotional, physical, and social functioning of an 
individual (Ware & Sherbourne, 1992).   
Allergies and Quality of Life 
Consequently, researchers have examined the difference between healthy controls 
and individuals with allergies to understand the impact the disease has on HRQOL.  
Researchers have found that individuals with allergies have significantly lower HRQOL 
in comparison to healthy controls (Bousquet et al, 1994; Metzler et al, 1997).  
Additionally, in an interesting allergen exposure task, where adults with allergies were 
exposed to specific allergic triggers, Ellis and colleagues (1999) found that participants 
had lower HRQOL during the allergen task than before.  In addition, Schatz (2007) 
looked at the HRQOL of adolescents and adults and found that individuals with allergies 
rated their symptoms as more severe than physician’s ratings, and, those individuals with 
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more symptomatic days had lower HRQOL.  This would imply that objective measures 
(physician report) of allergy severity may not truly reveal the impact of the disease on 
every individual; however, the patient reported severity (number of symptomatic days) 
may indeed relate to HRQOL.   
In addition to decreased levels of HRQOL, research has examined the impact of 
allergies on work/school performance and attendance, aspects typically measured by 
HRQOL domains.  In the Allergies in America survey, researchers found that 85% of 
surveyed individuals indicated allergies affected their lives; overall, allergies interfered 
with productivity at work in over half of the participants (HealthStar Communications, 
Schulman, Ronca, & Bucuvalas Inc., 2006).  The adults also indicated that, on average, 
their productivity at work decreased by 23% when their symptoms were severe 
(HealthStar Communications et al, 2006).  Lamb and colleagues (2006) calculated the 
total loss of productivity in 2006 due to allergies by incorporating the days of work 
missed and unproductive work time and found that $593 was lost per individual due to 
allergic diseases.  These findings are further corroborated by Wallace and colleagues 
(2008), who found that over 2 million school days and 3.5 million workdays are missed 
annually due to allergic rhinitis.  This data clearly shows the impact of the disease on 
individuals’ day to day functioning, and the various aspects of their lives the disease can 
affect.   
Other researchers have examined HRQOL in individuals with allergies in 
comparison with other chronic diseases.  Jolicoeur and colleagues (1994) examined 
impairment and quality of life in college students with allergies and with asthma, finding 
that students with allergies displayed greater impairment in their daily activities and 
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academic functioning than college students with asthma or those with both asthma and 
allergies. These findings suggest the importance of understanding the implications of 
allergies on the HRQOL of individuals with the disease.  
Overall the literature demonstrates reduced levels of HRQOL in children and 
adults with allergies, with the burden of the disease exemplified by the interference with 
productivity and absenteeism at work or school.  The following section examines a model 
that can help understand the psychosocial functioning of individuals with allergies and 
with asthma.  
Rolland’s Family Systems – Illness Model 
Rolland’s family systems illness (FSI) model may be used to help explain the 
psychosocial functioning in individuals with asthma and with allergies.  This model 
classifies chronic illnesses based on the psychosocial typology of illness, developmental 
time phases of the illness, and family system variables (Rolland, 1987).  The model 
further conceptualizes the typology of chronic illnesses into four categories, onset, 
course, outcome, and incapacitation (Rolland, 1987).  Onset of the disease is categorized 
by acute or gradual, while the course of the disease is progressive, constant, or relapsing.  
The outcome of the disease can be no effect, shortened life span, or death, while 
incapacitation is either present or absent (Rolland, 1987).  By classifying chronic 
illnesses in this manner, the model aims to better understand the relationship between the 
illness and psychosocial functioning.  Besides these categories, the model also looks at 
the development and phases of the illness: crisis, chronic, and terminal (Rolland, 1987).  
These time phases were developed to better understand the implications of the chronic 
illness for the individual.  The crisis phase describes when the individual becomes 
    
26 
 
oriented to the diagnosis of illness and begins to adjust to this change.  The chronic phase 
is the period of time between the initial adjustment to the illness and the progression to 
the terminal phase, where the individual maintains functioning in spite of the chronic 
illness.  The last phase or terminal phase is when the individual begins to prepare for 
death.  As an individual is diagnosed with an illness, the model incorporates these phases 
into understanding the psychosocial functioning of the affected individual.   Lastly, the 
model includes aspects of how family dynamics and family involvement impact the 
psychosocial adjustment of the individual with the illness and the family unit such as 
culture, family development, and belief systems (Rolland, 1987.)  
Figure 1. Rolland’s Family Systems – Illness Model 
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Figure 1.  Classification of chronic illnesses by psychosocial typology From: Rolland, 
J.S. (1987). 
The FSI model has been used with chronic illnesses to explain how disease 
characteristics can present differing constraints on individuals and family, and how these 
constraints may produce variability in the psychosocial functioning of the individuals and 
families affected by the chronic illness (Andrews, 2009; Hullmann, 2010).  As but one 
example, in a study examining psychosocial functioning in adolescent cancer survivors, 
Rait and colleagues (1992) found that the family involvement and cohesion impacted the 
future functioning of the cancer survivor, thus, showing the influence of the family on the 
psychosocial adjustment of the individual with a chronic illness.   
Furthermore, this typology of illnesses helps clarify the relationship between 
different chronic illnesses and the psychosocial functioning of individuals with these 
illnesses.  Within this model, allergies and asthma fall within the same grouping, with 
both diseases having acute onset, episodic course, non-fatal outcome, and are non-
incapacitating 
Chapter Summary 
(Rolland, 1987).  This model could help explain the psychosocial 
adjustment in individuals with allergies and with asthma, such that individuals with 
asthma and with allergies present analogous psychosocial functioning.   
 In summary, both asthma and allergies are highly prevalent chronic illnesses, with 
millions of individuals in the United States affected. Although the mortality from both 
diseases is low, the high levels of morbidity further underscore the need to understand 
these diseases.  Previous researchers have examined some of the psychosocial effects of 
the diseases independently and found that individuals have increased depressive and 
anxiety symptoms and lower HRQOL than healthy controls (e.g. Adams et al, 2004; 
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Cuffel et al, 1999).  However, the relationship between individuals with asthma and with 
allergies and the impact of psychosocial functioning in comparison to healthy controls is 
still relatively indistinct. 






THE PRESENT STUDY 
The previous literature demonstrates evidence of negative psychosocial outcomes 
in a consistent subset of individuals with asthma and with allergies. These pejorative 
outcomes include increased depressive and anxiety symptoms as well as lower HRQOL 
in individuals with asthma and with allergies.  Although anxiety and depressive 
symptoms in individuals with asthma and with allergies have been previously examined 
in preliminary studies (e.g. Adams et al, 2004; Cuffel et al, 1999; Kagan et al, 1991), 
often the symptoms were studied as a single construct, thus clouding the relationship 
between the chronic illness and specific psychosocial construct.  Additionally, much of 
the HRQOL literature in individuals with allergies examines children with specific 
allergens, or on the implications of medication usage on asthma or allergy symptoms.  
Furthermore, the adolescent and young adult (AYA) population is understudied in 
chronic illnesses, as research mostly focuses on either younger children or older adults 
with chronic illnesses.   
Although researchers have provided preliminary work on the psychological 
aspects affecting individuals with asthma and with allergies, their research has rarely 
examined the relationship between asthma and allergies and the psychological impacts of 
these chronic illnesses in relation to healthy controls.  Using Rolland’s typology for 
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chronic illnesses, individuals with asthma and with allergies should express analogous 
negative psychosocial outcomes.  Thus, the current study expanded upon the current 
research to understand the psychosocial functioning of AYAs with asthma and AYAs 
with allergies in comparison with healthy AYAs.   
 The following aims and hypotheses guided this research: 
Aim 1: To examine the rates of psychological distress, specifically depressive symptoms 
and anxiety symptoms, between AYAs with allergies, with asthma, and healthy controls.   
Hypothesis 1: It was hypothesized that AYAs with asthma and AYAs with 
allergies would have higher levels of anxiety symptoms than the healthy controls. 
Hypothesis 2: It was hypothesized that AYAs with asthma and AYAs with 
allergies would have higher levels of depressive symptoms than the healthy 
controls. 
Hypothesis 3: It was hypothesized that there would be no difference between the 
levels of anxiety and depressive symptoms in AYAs with allergies or asthma.  
Aim 2: To examine emotional and physical quality of life between AYAs with allergies, 
with asthma, and healthy controls.   
Hypothesis 4: It was hypothesized that AYAs with asthma and AYAs with 
allergies would report lower physical and emotional quality of life than the 
healthy controls.   
Hypothesis 5: It was hypothesized that there would be no difference between the 
emotional or physical quality of life in AYAs with allergies or asthma. 
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 To test these hypotheses, de-identified, archival data from a large sample of 
AYAs with allergies, with asthma, and with no chronic illnesses was examined.  Each 
participant completed a demographic form in addition to measures of anxiety 
symptomatology, depressive symptomatology, and health-related quality of life.  The 
following chapter expands upon the method, participants, and procedure.  







Adolescents and young adults (AYAs) diagnosed with either allergies (N = 120), 
asthma (N = 120), or no chronic illness (N = 120) were recruited from two larger 
ongoing studies examining the psychosocial functioning of college students with chronic 
health conditions.  Informed consent and the study protocol were explained and obtained 
prior to beginning any procedures.  The participants were matched on age, sex, and 
ethnicity following data collection.  When an exact match on age was not found, a 
participant with the closest age was chosen as the match.  As such, nonsignificant 
variability was observed in the age of the participants across samples.  AYAs with 
allergies ranged from 18-25 years old (M = 19.59, SD = 1.59), as did AYAs with asthma 
(M = 19.59, SD = 1.43), and healthy AYAs ranged from 18 to 29 years old (M = 19.57, 
SD = 1.55).  The majority of participants were female (58.3%) and most self-identified as 
Caucasian (74.2%).  Participants also self-identified as African American (6.7%),  Native 
American (11.7%), Multiracial (4.2%), Hispanic (1.7%),, and Other (1.7%).  The ethnic 
breakdown of the current sample is consistent with the ethnic distribution of the 
university in which this study was conducted.   
Participants 
Measures 
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A demographic questionnaire was completed and provided information regarding 
the participant’s age, sex, ethnicity, education level, and illness information (illness type, 
age of onset, self-report severity, and treatment methods).   
Demographic Questionnaire. 
Center for Epidemiologic Studies Depression Scale (CES-D). 
 
The CES-D is a 20-
item self-report measure developed to assess depressive symptoms (Radloff, 1977).  For 
each item, the participant designates whether he or she has experienced the symptom 
within the last week.  Each of the items is ranked on a 4-point Likert scale ranging from 
occurring ‘rarely or none of the time’ to ‘most or all of the time’.  Responses from all 20 
items were combined to calculate a total score; this total score was used to determine 
level of depressive symptomatology.  Total scores on the CES-D range from 0 – 60, with 
higher scores representing greater levels of depression, and scores above 16 
demonstrating a clinically significant level of distress.  A high level (.85-.90) of internal 
consistency reliability has been demonstrated with the CES-D (Radloff, 1971).  
Cronbach’s alpha for the CES-D total score for the current sample was .908.   
Zung Self-Rating Anxiety Scale (SAS).  The SAS is a 20-item self-report measure 
developed to assess anxiety symptoms (Zung, 1971).  For each item, the participant 
indicates whether he or she has experienced the symptom within the last week.  Each of 
the items is ranked on a 4-part Likert scale ranging from occurring ‘none or a little of the 
time’ to ‘most of the time’.  Responses from all 20 items were combined to calculate a 
total score; this total score was used to determine the level of anxiety symptomatology 
each participant exhibits.  Scores on the SAS range from 20 – 80, with 20 – 44 signifying 
normal anxiety levels, 45 – 59 signifying mild to moderate anxiety levels, 60 – 74 
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signifying severe anxiety levels, and 75 – 80 signifying extreme anxiety levels.  A high 
level (.71) of internal consistency reliability has been demonstrated with the SAS (Zung, 
1971).  Cronbach’s alpha for the SAS total score for the current sample was .860.   
SF-36 Health Survey Questionnaire (SF-36). The SF-36 is a widely utilized 36-
item self-report measure of health-related quality of life (HRQOL) and general health 
status.  This measure assesses health status across eight domains: physical functioning, 
role limitations due to physical health, bodily pain, general health perceptions, vitality, 
social functioning, role limitation due to emotional problems, and mental health.  Scores 
from the SF-36 range from 0 (poorest health status) to 100 (best health status).  The 
questionnaire yields a score for each domain, including a Physical Component Summary 
Score (PCS), a Mental Component Summary Score (MCS), and an overall score 
encompassing all eight domains.  The PCS is comprised of physical functioning, role-
physical, bodily pain, and general health domains.  The MCS is comprised of vitality, 
social functioning, role-emotional, and mental health domains.  Both the PCS and MCS 
were used in this study to determine the quality of life for each participant.  A high level 
(.91) of internal consistency reliability has been demonstrated within the SF-36 
(Bousquet, et al., 1994).  Cronbach’s alpha for the SF-36 summary score for the current 
sample was .880.   
The participants were recruited from an online participant pool for undergraduate 
students at a large Midwestern university.  Participant self-identified themselves as 
having asthma, allergies, or no chronic illnesses.  The participants with asthma were 
recruited online, and then came to the laboratory to complete the study measures as part 
Procedure 
    
35 
 
of a larger study examining psychosocial adjustment in college students with chronic 
illnesses.  Those participants with allergies and no chronic illnesses were both be 
recruited online and completed the study measures online as part of a larger study 
examining psychosocial adjustment in college students with and without allergies.  
Although the data collection method varies as the asthma participants completed the 
measure in person while the allergy and healthy participants completed the measures 
online, research has shown that web-based surveys are compatible and consistent with 
results from in-person surveys (Buchanan & Smith, 1999; Gosling, Vazire, Srivastave, & 
John, 2004).  Both studies were IRB- approved, and all the participants received research 
credit for an undergraduate class for participating in the study.  







Preliminary Analyses  
Descriptive information (i.e., range, mean, and standard deviation) for the 
variables of interest can be found in Table 1. After examining the distribution of the data 
for each of the variables of interest, the data were within the parameters established by 
Tabachnick and Fidell for both skewness and kurtosis (2007).  Additionally, a series of 
bivariate correlations was conducted to determine the relationship between demographic 
variables (i.e., age, sex, and ethnicity) and outcome variables (i.e., CES-D Total Score, 
SAS Total Score, and SF-36 PCS and MCS); results are depicted in Table 2.  Because of 
the significant correlation identified between SAS and CES-D total scores to both the SF-
36 MCS and SF-36 PCS, the SAS and CES-D total scores were used as covariates in the 
analyses of SF-36 MCS and SF-36 PCS.  In the following ANOVA analyses, the Welch 
procedure was used if the data violated the homogeneity of variances assumption.   
An ANOVA (Analysis of Variance; allergies vs. asthma vs. healthy) was 
conducted to examine differences among the disease groups for clinical cutoff scores for 
anxiety and depressive symptoms. The percentages and number of participants reporting 
clinically significant levels of depression and anxiety can be found in Table 3. A clinical 
cutoff score of 16 or greater (Radloff, 1977) was used to determine clinically significant
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depressive symptoms, while a clinical cutoff score of 45 or greater (Zung, 1971) was 
used to determine clinically significant anxiety symptoms. Results revealed significant 
differences between the groups for the CES-D total score, F(2, 237.02) = 5.156, p = .006, 
such that the number of AYAs with allergies reporting depressive symptoms in the 
clinical range was significantly greater than the number of healthy AYAs. The number of 
AYAs with asthma did not differ significantly from AYAs with allergies or healthy 
AYAs on depressive symptoms.  For the SAS total score, the results revealed significant 
differences between the groups, F(2, 212.36) = 10.876, p < .001, with post hoc 
comparisons indicating that the number of AYAs with allergies reporting anxious 
symptoms in the clinical range was significantly greater than the number of healthy 
AYAs and greater than the number of AYAs with asthma. The number of AYAs with 
asthma did not differ significantly from the healthy AYAs on anxious symptoms.  
Primary Analyses 
To address aim 1 and test the hypotheses that AYAs with asthma and AYAs with 
allergies have higher levels of anxiety and depressive symptoms than healthy controls, 
and that AYAs with asthma and AYAs with allergies do not differ on anxiety or 
depressive symptoms, two one-way ANOVAs (Analysis of Variance; allergies vs. asthma 
vs. healthy) were conducted across the disease groups using total scores on the CES-D 
and SAS.  For depressive symptoms, results revealed significant differences between the 
groups, F(2, 357) = 5.504, p = .004, partial η2 = .030, observed power = .853. Tukey’s 
post hoc comparisons indicated that AYAs with allergies had significantly higher levels 
of depressive symptoms than healthy AYAs.  AYAs with asthma did not differ 
significantly from AYAs with allergies, or healthy AYAs, see figure 2.   
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Figure 2. Total depression score across disease group 
 
Note. CES-D = Center for Epidemiologic Studies Depression Scale. ** p < .01 
For anxiety symptoms, a Welch test was used to adjust for violation of the 
homogeneity of variance. The results revealed significant differences between the groups, 
F(2, 233.02) = 14.041, p < .001, partial η2 
Figure 3. Total anxiety score across disease group 
= .070, observed power = .996.  Tukey’s post 
hoc comparisons indicated that AYAs with allergies had significantly higher levels of 
anxiety symptoms than healthy AYAs, and AYAs with allergies had significantly higher 
levels of anxiety symptoms then AYAs with asthma.  Additionally, AYAs with asthma 
had significantly higher levels of anxiety symptoms than healthy AYAs, see figure 3. 
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 To address aim 2 and test the hypotheses that AYAs with asthma and AYAs with 
allergies have lower levels of mental and physical HRQOL than healthy controls, and that 
AYAs with asthma and AYAs with allergies do not differ on mental or physical HRQOL, 
two one-way ANCOVAs (Analysis of Covariance; allergies vs. asthma vs. healthy) were 
conducted across the disease groups on the SF-36 MCS and SF-36 PCS, which were used 
to assess mental and physical HRQOL, respectively, see figures 4 and 5.   
Figure 4. Total physical health-related quality of life across disease group 
 
Note: SF-36 PCS = SF-36 Health Survey Questionnaire Physical Component Summary 
Score. ** p < .01.  p < .01 
Figure 5.Total mental health-related quality of life across disease group
 
Note: SF-36 MCS = SF-36 Health Survey Questionnaire Mental Component Summary 
Score. 
**  
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The total depressive and anxiety scores were used as covariates in each of the 
analyses after bivariate correlations revealed significant correlations to the SF-36 MCS 
and SF-36 PCS, respectably.  For mental HRQOL, results revealed that the covariate, 
total depressive symptoms, was significantly related to the mental HRQOL, F(1, 355) = 
102.104, p < .001, partial η2 = .223, observed power = 1.0.  Total anxiety symptoms were 
also significantly related to mental HRQOL, F(1, 355) = 29.797, p < .001, partial η2 = 
.077, observed power = 1.0.   There was no significant effect of disease group on mental 
HRQOL after controlling for depressive and anxiety symptoms, p > .05.  For physical 
HRQOL, results revealed that the covariate, total depressive symptoms was not 
significantly related to the mental HRQOL, p > .05; however, total anxiety symptoms 
was significantly related to mental HRQOL, F(1, 355) = 77.549, p < .001, partial η2 = 
.179, observed power = 1.0.   There was also a significant effect of disease group on 
physical HRQOL after controlling for depressive and anxiety symptoms, F(2, 355) = 
10.457, p < .001, partial η2 
Exploratory Analyses 
= .056, observed power = .988.  Using Bonferroni’s 
adjustments, healthy AYAs had significantly higher physical HRQOL than AYAs with 
asthma, p < .001, and healthy AYAs had significantly higher physical HRQOL then 
AYAs with allergies, p = .008.  AYAs with allergies did not statistically differ from 
AYAs with asthma on physical HRQOL, p > .05. 
Previous studies have utilized the subscales for the SF-36 to better understand 
specific differences between the various domains (Ware & Sherbourne, 1992).  Thus, to 
better elucidate how AYAs with asthma, with allergies, and healthy AYAs differed on 
each of the SF-36 subscales, exploratory one-way ANOVAs were conducted.  Results 
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indicated a significant difference between the illness groups on the subscale of physical 
functioning, F(2,150.73) = 9.35, p < .000, such that AYAs with allergies (M = 86.28, SD 
= 23.47) and AYAs with asthma (M= 83.86, SD = 16.11) were experiencing poorer 
physical functioning than healthy AYAs (M = 94.04, SD = 14.30), AYAs with asthma did 
not differ from AYAs with allergies on physical functioning.  Results indicated a 
significant difference between the illness groups on the subscale of role physical, 
F(2,151.34) = 5.82, p = .004, such that AYAs with allergies (M = 79.81, SD = 24.07) 
were experiencing poorer role physical than healthy AYAs (M = 90.71, SD = 16.54), 
AYAs with asthma did not differ from AYAs with allergies or healthy AYAs.  
Additionally, the results indicated a significant difference between the illness groups on 
the subscale of social functioning, F(2,153.57) = 3.59, p = .03, such that AYAs with 
allergies (M = 77.53, SD = 23.80) were  experiencing poorer social functioning than 
AYAs with asthma (M = 86.23, SD = 17.40); healthy AYAs (M = 84.81, SD = 20.28) did 
not differ from AYAs with allergies or with asthma on social functioning.  The results 
indicated a significant difference between the illness groups on the subscale of bodily 
pain, F(2,145.71) = 11.85, p < .000, such that AYAs with allergies (M = 77.53, SD = 
20.83) and AYAs with asthma (M= 81.90, SD = 17.90) reported higher levels of bodily 
pain than healthy AYAs (M = 89.43, SD = 11.52); AYAs with asthma did not differ from 
AYAs with allergies on the subscale of bodily pain.  Lastly, the results indicated a 
significant difference between the illness groups on the subscale of general health, 
F(2,150.83) = 9.48, p < .000, such that AYAs with allergies (M = 67.67, SD = 21.06) and 
AYAs with asthma (M= 66.49, SD = 21.90) were experiencing poorer general health than 
healthy AYAs (M = 77.53, SD = 14.95), while, AYAs with asthma did not differ from 
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AYAs with allergies on general health.  There were no significant differences between 
the disease groups on the SF-36 subscales of mental health, vitality, or role emotional. 
   







         The current study sought to elucidate the differences in anxiety symptoms, 
depressive symptoms, and HRQOL in adolescents and young adults (AYAs) with 
allergies, AYAs with asthma, and healthy AYAs.  It was hypothesized that AYAs with 
allergies and AYAs with asthma would exhibit higher levels of depressive and anxiety 
symptoms than healthy AYAs, and that AYAs with allergies and AYAs with asthma 
would exhibit poorer HRQOL than healthy AYAs.  Our results partially supported these 
hypotheses, such that AYAs with allergies demonstrated higher levels of depressive 
symptoms than healthy AYAs, and AYAs with allergies having higher levels of anxiety 
symptoms than AYAs with asthma and healthy AYAs.  AYAs with asthma had higher 
anxiety symptoms than healthy AYAs, while AYAs with allergies and AYAs with 
asthma demonstrated poorer physical HRQOL than healthy AYAs after controlling for 
anxiety and depressive symptoms.  Collectively, these results suggest that AYAs with 
allergies are indeed experiencing psychosocial concerns on par with or even greater than 
AYAs with asthma.  An examination of the means revealed that AYAs with allergies are 
actually experiencing greater anxiety and depressive symptoms as well as poorer mental 
and physical HRQOL than AYAs with asthma; however, statistical differences were only 
observed on anxiety symptoms.    
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Consistent with previous research (Fernandes et al, 2010; Gillaspy et al, 2002; 
Katon et al, 2007; Buske-Kirschbaum et al, 2008; Cuffel et al, 1999), AYAs with asthma 
and AYAs with allergies displayed higher levels of anxiety symptoms than the healthy 
controls.  Notably, AYAs with allergies also displayed higher levels of anxiety symptoms 
than AYAs with asthma.  Although speculative, this finding suggests that AYAs with 
allergies may be having increased difficultly managing aspects of their disease.  In other 
words, these symptoms may be consequences of the symptoms allergies reflect increasing 
apprehension, worry, and dysporhia.  Notably, treatment action plans are often developed 
for individuals with asthma; however, no such plans exist to help individuals with 
allergies plan and strategize the treatment of their symptoms (Douglass et al, 2002).  
Furthermore, many allergy sufferers believe they have to endure their symptoms, and that 
treatment options are only palliative in nature (Zellerbach, 2000).   
 The current findings are consistent with previous research, such that AYAs with 
allergies may be at risk for higher depressive symptoms in comparison to their healthy 
counterparts (Patten & Williams, 2007).  However, inconsistent with previous research 
(Gillaspy et al, 2002; Seigel et al, 1990), AYAs with asthma did not demonstrate higher 
levels of depressive symptomatology than their healthy peers.  Although speculative, 
perhaps the uncertainty of asthma symptoms may be more likely to lead to worry and 
anxiety symptoms as opposes to depressive symptoms.   It may also be that the AYAs 
with asthma in this study largely evidenced only mild disease, and as a result, may not 
have experienced accompanying depressive symptoms related to disease severity.  
 Previous research has also found that AYAs with allergies and AYAs with asthma 
have lower mental and physical HRQOL (Adam et al, 2004; Schemier, Chan, & Leidy, 
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1998); however, many of these studies failed to control for anxiety and depressive 
symptoms.  For mental HRQOL, we found that both anxiety and depression symptoms to 
be significantly related to each other; however, after controlling for anxiety and 
depressive symptoms, we did not find any group difference on mental HRQOL between 
AYAs with asthma, AYAs with allergies, and healthy AYAs.  This suggests that the 
disease group differences in mental HRQOL may indeed be accounted by the differences 
in anxiety and depressive symptoms.   
For physical HRQOL, we found that AYAs with allergies and AYAs with asthma 
have lower levels of physical HRQOL than their healthy counterparts after controlling for 
anxiety and depressive symptoms.  This is consistent with previous research that shows 
individuals with asthma and individuals with allergies have poorer HRQOL than healthy 
controls (Bousquet, Bullinger et al, 1994, Bousquet, Knani et al, 1994).  This also 
suggests that AYAs with asthma and AYAs with allergies may indeed be experiencing 
more difficulties with work, school, and daily activities, independent of any anxiety or 
depressive symptoms they may have.  This finding underscores the burden of allergies 
and asthma on those individuals with these diseases (Nathan, 2007; Schatz, 2007; Barnett 
& Nurmagambetov, 2011).   
Interestingly, the exploratory analyses showed that AYAs with allergies reported 
lower levels of social functioning than AYAs with asthma, but both AYAs with allergies 
and with asthma did not differ from healthy AYAs suggesting that AYAs with allergies 
are having greater difficulties with social functioning than AYAs with asthma.  Again, 
while speculative, these results that AYAs with allergies have increased difficulties, 
especially with social functioning in comparison to AYAs with asthma.  For the subscales 
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of physical functioning, role physical, bodily pain, and general health, AYAs with asthma 
and AYAs with allergies had significantly worse functioning than healthy AYAs which is 
consistent with previous research (Bousquet, Bullinger et al, 1994, Bousquet, Knani et al, 
1994).  The subscales of role emotional, vitality, mental health, and health transition did 
not differ across the illness groups, perhaps suggesting these aspects of HRQOL are more 
consistent across disease groups.   
Important to note, high percentages of AYAs met the suggested clinical cutoffs 
based on their reported anxiety and depressive symptoms, especially AYAs with 
allergies, as 42.5 and 21.7 percent met the cutoffs for depressive and anxiety symptoms, 
respectively.  This suggests that although we utilized a nonclinical population, AYAs are 
indeed having significant difficulties and that the psychosocial adjustment of AYAs with 
allergies and asthma should be assessed periodically as they transition to adulthood.  
Since the majority of AYAs treated for allergies and asthma are seen at primary care 
physicians or university health care settings, the healthcare professionals at these 
locations should assess for anxiety and depressive symptoms, as well as any other health-
related concerns.  Those individuals who are at risk for developing pejorative 
psychosocial adjustment outcomes may benefit from cognitive behavioral interventions 
to address their negative thoughts and behaviors.        
There are several limitations to the current study. First the participants were 
recruited from a large Midwestern university, and as a non-clinical population, may not 
be representative of individuals with more severe symptoms.    Despite the non-clinical 
nature of this population, there were high numbers of AYAs meeting clinical cutoffs for 
anxiety and depression.  Next, the AYAs with asthma completed the study measures in 
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person, while the AYAs with allergies and healthy AYAs completed the study measures 
online.  However, researchers have found that information collected online is of similar 
quality to information collected in person (Gosling, Vazire, Srivastava, & John, 2004).  
The asthma and allergies diagnoses were also self-reported and not confirmed with a 
physician report.  Additionally, the psychosocial functioning was assessed using self-
report measures, so the results may reflect shared method variance.  Finally, the AYAs 
with allergies denied any history of asthma; however, the AYAs with asthma were not 
questioned regarding their allergy status.   
Overall, the current study builds upon past research examining the impact of 
anxiety symptoms, depressive symptoms, and HRQOL of individuals with allergies and 
asthma.  The results of the study fail to confirm Rolland’s model that AYAs with 
allergies and asthma have similar psychosocial functioning.   Perhaps medical 
advancements with the treatment of asthma over the last several decades have changed 
the characteristics and the disease is no longer comparable on onset, course, outcome, and 
incapacitation to allergies. The results from this study suggest a need for a revision to this 
model incorporating updated medical treatment advances since the model was developed.  
The current study adds to the literature in examining the relationship between AYAs with 
allergies and with asthma, specifically addressing the psychosocial functioning of young 
adults, an understudied population in chronic illness literature (Pai & Schwartz, 2011). 
Future studies may benefit from examining cognitive appraisal variables, such as 
illness intrusiveness and illness uncertainty, which may impact the psychosocial 
functioning of AYAs with chronic illnesses (Fedele et al, 2009, Hommel, 2003).  
Additional studies may also want to examine the impact of illness severity in the 
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development of psychosocial functioning as past research suggests that illness severity 
may contribute to anxiety symptoms (Hommel et al, 2003).  Finally, longitudinal 
examination of the relationship between severity, disease, and psychosocial functioning 
may be important for the development of specific interventions for individuals with 
allergies and asthma.  
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Demographic Information – Asthma  
Participant #:____________________   
BACKGROUND INFORMATION 
 
1.  Age: _______________ 
 
2.  Sex: M F 
  1 2 
 
3.  Race 1 African-American 




6 Biracial, please specify: ________________________________ 
7 Other, please specify:  _________________________________ 
 
4.  Highest Level of Education Obtained: 
1 Middle School 
2 High School 





4 College Degree 
5 Post-Graduate Degree 
 
 
4a. What is your current (or intended) major? __________________________________ 
 
4c. What is the highest math class you have taken?  
1. Applications of Modern Mathematics (1493) 
2. College Algebra (1513) 
3. Trigonometry  (1613) 
4.  Calculus (2103, 2123, 2133, 2144) 
5. Calculus II or III (2153 or 2163) 
6. 3000s level Math course 
7. 4000s level Math course 
8. Other, please specify:______________________ 
 
4d. What grades do you usually receive in math?    
 
As (100-90) Bs (89-80) Cs (79-70) Ds (69-60) Fs (59 or below) Not Sure 
5.  Marital Status: 1 Never Married 
2 Married 




4 Cohabitating/Living with Partner 
5 Widowed 
6 Other, please specify: _______________________________ 
 
6.  If married, spouse’s occupation:  ____________________________________________ 
 
7.  Parent’s occupation:  Father:___________________ Mother: ___________________ 
 
8.  Parent’s highest level of education obtained: 
     Father: ___________________________   Mother: ___________________________ 
 
9.  Do you live with your parents even part-time (including weekends or summers)?  _________ 
 
 
10.  Are you currently taking any psychoactive medication (e.g., antidepressants, anti-anxiety)? 
 YES  NO 
 1  2 
 
11.  Have you ever been treated by a physician for a medical condition for more than three 
consecutive months in any given year?  (For example:  May, June, and July, 1999) 
 YES  NO 
 1  2 
 
12.  Have you ever been hospitalized continuously for a medical condition for more than one 
month? 
 YES  NO 
 1  2 
 
13. In the last hour, have you consumed any caffeine? 
YES  NO 
1  2 
 
 
14. In the last hour, have you eaten a meal? 
YES  NO 
1  2 
15. In the last hour, have you taken any medication? 
YES  NO 
1  2 
 
If yes, what was the medication? _______________________________________ 
16. In the last hour, have you slept or taken a nap? 
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YES  NO 
1  2 
 
 
17.  Do you have a chronic illness? 
 YES  NO 
 1  2 
 
IF NO, PLEASE ANSWER 17B AND THEN NOTIFY THE 
EXPERIMENTER.  THANK YOU.  IF YES, PLEASE GO ON 
TO QUESTION 18. 
 
17B.  Please estimate the number of school and/or work days you 
missed during the last academic year (2008-2009) for medical 
reasons.  (If you are a freshman in college and you were in high 
school during the 2008-2009 academic year, please refer to your 
senior year of high school.  If you were not in school during the 2008-
2009 academic year, please list days missed from work only.) 
 SCHOOL: _________________ 
 WORK:  __________________ 
 
 
18.  Do you have asthma? 
 YES  NO 
 1  2 
If you have another chronic illness in addition to asthma, please specify the type or types of 
condition(s):__________________________________________________________ 
 
19.  Have you or another family member ever received any type of psychological counseling or 
therapy? 




If yes, was your counseling related to your asthma?  
 YES  NO 
 1  2 
20.  Are you currently taking any medications for your asthma? 
 YES  NO 
 1  2 
 
If yes, please specify the type of medication(s) and how frequently you take the medication(s): 
 Type     Frequency    
 a.  _________________________      ____________________________ 
Is this medication an inhaler?   YES    or     NO 
Does this medication include steroids (i.e., corticosteroid or glucocorticoid)? YES    or   NO                
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                         or    Not sure 
  
Type     Frequency 
 b.  _________________________  ____________________________ 
Is this medication an inhaler?   YES    or     NO 
Does this medication include steroids (i.e., corticosteroid or glucocorticoid)? YES    or   NO                
                         or    Not sure 
 
 
 Type     Frequency  
 c.  _________________________  ____________________________ 
 
Is this medication an inhaler?   YES    or     NO 
Does this medication include steroids (i.e., corticosteroid or glucocorticoid)? YES    or   NO                
                         or    Not sure 
 
21.  At what age did you have your first asthma attack?  _____________________________ 
 
22.  At what age were you diagnosed with asthma? _________________________________ 
23.  Are you presently receiving any medical treatment from a physician for your asthma? 
 YES  NO 
 1  2 
 
If yes, please indicate the number of visits to your physician in the past 6 months.  ___________ 
24.  Do you have asthma attacks only during a certain season (SEASONAL) or all-year round 
(PERENNIAL)? 
 SEASONAL  PERENNIAL 
 1   2 
 
25.  How severe
 
 do you think your asthma has been in the past year? 
1             2           3            4           5          6                7 
Mild                  Moderate          Severe  Respiratory  
             Failure 
 
Mild = 1 or 2 attacks per week; as many as two episodes of nighttime cough a month; good 
exercise tolerance; no symptoms between attacks; bronchospasm responds to bronchodilator. 
 
Moderate = More than 2 attacks per week; symptoms between attacks; symptoms affect sleep, 
activity level, or work performance; bronchospasm responds to bronchodilator; reduced exercise 
tolerance; coughing; chest tightness, wheezing; seeking emergency room treatment more than 
three times per year.   
 
Severe = Daily wheezing; sudden, severe attacks; limited exercise tolerance and activity level; 
sleep is disrupted; bronchospasm does not always respond to bronchodilator; poor work 
attendance; mild tachycardia (excessively rapid heartbeat); tachypnea (excessively rapid 
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breathing); difficulty speaking in complete sentences; seeking emergency care more than 3 times 
per year.   
 
Respiratory Failure = Increased tachycardia (excessively rapid heartbeat); tachypnea 
(excessively rapid breathing); wheezing; reduced, poor air exchange;  uses accessory muscles 
(e.g., arms) to sit up, with perspiration; confusion; lethargy; altered consciousness. 
 
 
26.  How controllable
 
 do you think your asthma is? 
1              2              3              4              5             6           7 
Entirely        Somewhat          Mostly             Entirely 




27.  Please estimate the number of school and/or work days you missed during the last academic 
year (e.g., 2008-2009) as a result of your asthma or asthma-related symptoms.  (If you are a 
freshman in college and you were in high school during the 2008-2009 academic year, please 
refer to your senior year of high school.  If you were not in school during the 2008-2009 
academic year, please list days from work only.) 
 SCHOOL: _________________ 
 WORK:  __________________ 
 
28.  Please estimate the number of school and/or work days you missed during the last academic 
year (2008-2009) for medical reasons other than asthma.  (If you are a freshman in college and 
you were in high school during the 2008-2009 academic year, please refer to your senior year of 
high school.  If you were not in school during the 2008-2009 academic year, please list days 
from work only.) 
 SCHOOL: _________________ 
 WORK:  __________________ 
 
29.  During the 2008-2009 academic year, did you ever attend class when you had asthma 
symptoms? 
 YES  NO 
 1  2 
 
If yes, please estimate the number of days you did attend class when you had asthma symptoms. 
__________________________ 
 
If yes, please circle the number that indicates how much the asthma symptoms interfered with 
your normal daily class routine (i.e., taking notes, taking an exam, participating in a laboratory). 
 
1            2        3                4             5              6                    7 
No          Mild       Moderate  Interfered a 
Interference      Interference     Interference  Great Deal 





30.  During the 2008-2009 academic year, did you ever attend work when you had asthma 
symptoms? 
YES  NO 
1 2 
 
If yes, please estimate the number of days you did attend work when you had asthma symptoms. 
 
If yes, please circle the number that indicates how much the asthma symptoms interfered with 
your normal work routine (i.e., getting to work on time; completing job tasks efficiently). 
 
1      2  3  4  5  6  7 
No             Mild       Moderate  Interfered a 
Interference      Interference     Interference              Great Deal 
 
31.  During the 2008-2009 academic year, do you feel that your asthma interfered with your 
social life? 
 YES  NO 
 1  2 
 
If yes, please circle the number that indicates how much your asthma symptoms interfered with 
your social life. 
 
1       2  3  4  5  6  7 
No             Mild       Moderate  Interfered a 
Interference      Interference     Interference              Great Deal 
 
 
Do not fill out below this line 
________________________________________________________________ 
  
Interrupted Demographic Form to take T3 (form took longer than 15 minutes) (yes or no):  
________ 
Finished Demographic Form before T3 (yes or no): ______________ 
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Demographic Form - Allergies 
Do you have allergies? 
_______  Yes    _______  No 
 
 
Have you also been diagnosed with asthma? 
 
_______  Yes    _______  No 
 
 
What are you allergic to?  Please mark all that apply. 
 
Environmental Allergens (i.e., pollen, dust, mold, grass, etc.):  
____  No   ______  Yes, please specify:  ____________________ 
 
Animals (i.e., animal dander, animal saliva, insect bites, etc.):  
____  No   ______  Yes, please specify:  ____________________ 
 
Food Allergens (i.e., milk, eggs, peanuts, tree nuts, fish, shellfish, soy, wheat, etc.):  
____  No   ______  Yes, please specify:  ____________________ 
 
Other Allergens (i.e., latex, metals, penicillin, etc.):  
____  No   ______  Yes, please specify:  ____________________ 
How were you diagnosed with allergies?  
_____ reaction to allergen _____ skin prick test _____ allergen patch test 
_____ blood test        _____ oral challenge test   
_____ other, please describe: _______________________________________________  
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Have you ever suffered from an allergy attack that required you to go to the doctor or 
hospital? 
_______  Yes    _______  No 
 
 
What are you currently doing to treat your allergies?  Please mark all that apply. 
 
_____ topical cream/ointment _____ antihistamine  _____ decongestant 




How severe have your allergies been over the past 12 months? 
No reaction Mild  Moderate Severe  Extremely severe 
 
Do you suffer from seasonal allergies? 
_______  Yes    _______  No 
 
If you marked “Yes”, which season is worst for your allergies? 




During the worst 1-month period in the 12 months, how often did you suffer from an 
allergic reaction?  
Every day 
4-7 days a week 
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1-3 days a week 
1-5 days a month 
Never 
In the past 12 months, how many times did you see your physician for your allergies? 
    ___ 0 times 
    ___ 1-2 times  
    ___ 3-5 times  
    ___ 5-10 times  










_____ Caucasian _____ African American _____ Hispanic _____ Asian  
 




_____ Heterosexual     ______ Homosexual  _____ Bisexual _____ Other 




 Highest Level of Education Obtained: 
6 Middle School 
7 High School 





9 College Degree 
10 Post-Graduate Degree 
 
What is your current (or intended) major? __________________________________ 
 
Marital Status: 1 Never Married 
7 Married 
8 Divorced 
9 Cohabitating/Living with Partner 
10 Widowed 
11 Other, please specify: _______________________________ 
 
Hometown:  ____________________ 
 
Number of years living in Stillwater, OK:  ______________________ 
  





Below is a list of the ways you might have felt or behaved. Please tell me how often you have 
felt this way in the past week
 
. 
DURING THE PAST WEEK 
 
 Rarely or none   Some or a little         Occasionally or a       Most or all 
    of the time       of the time    moderate amount of time       of the time 
(less than 1 day)              (1 – 2 days)                        (3 – 4 days)      (5 – 7 days) 
 
 0   1         2    3 
 
 ______  1. I was bothered by things that usually don’t bother me. 
 
______  2. I did not feel like eating; my appetite was poor. 
 
______  3. I felt that I could not shake off the blues even with help from my family or  
                  friends. 
    
______  4. I felt I was just as good as other people. 
 
______  5. I had trouble keeping my mind on what I was doing. 
 
______  6. I felt depressed. 




______  7. I felt that everything I did was an effort. 
 
______  8. I felt hopeful about the future. 
 
______  9. I thought my life had been a failure. 
 
______ 10. I felt fearful. 
 
______ 11. My sleep was restless. 
 
______ 12. I was happy. 
 
______ 13. I talked less than usual. 
 
______ 14. I felt lonely. 
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DURING THE PAST WEEK 
 
Rarely or none   Some or a little         Occasionally or a       Most or all 
    of the time       of the time    moderate amount of time       of the time 
(less than 1 day)              (1 – 2 days)                        (3 – 4 days)      (5 – 7 days) 
 
 0   1         2    3 
 
 
______ 16. I enjoyed life. 
 
______ 17. I had crying spells. 
 
______ 18. I felt sad. 
 
______ 19. I felt that people dislike me. 
 











Instructions: Based on how you felt in the last week, reply to the following questions using one 
of the four replies below. 
 
None or a little 
of the time 
Some 
of the time 
A large part 
of the time 
Most 
of the time 
1 2 3 4 
     
______  1. I feel more nervous and anxious than usual.  
______  2. I feel afraid for no reason at all. 
______  3. I get upset easily or feel panicky. 
______  4. I fell like I’m falling apart and going to pieces 
______  5. I feel that everything is all right and nothing bad will happen 
______  6. My arms and legs shake and tremble. 
______  7. I am bothered by headaches, neck, and back pains. 
______  8. I feel weak and get tired easily. 
______  9. I feel calm and can sit still easily. 
______  10. I can feel my heart beating fast. 
None or a little 
of the time 
Some 
of the time 
A large part 
of the time 
Most 
of the time 




______  11. I am bothered by dizzy spells. 
______  12. I have fainting spells or feel like it. 
______  13. I can breathe in and out easily. 
______  14. I get feelings of numbness and tingling in my fingers and toes. 
______  15. I am bothered by stomach aches or indigestion. 
______  16. I have to empty my bladder often. 
______  17. My hands are usually warm and dry. 
______  18. My face gets hot and blushes. 
______  19. I fall asleep easily and get a good night’s rest. 
______  20. I have nightmares. 
 
  
1 2 3 4 




Your Health and Well-Being 
 
 
This survey asks for your views about your health.  This information will help keep track 
of how you feel and how well you are able to do your usual activities.  Thank you for 
completing this survey! 
For each of the following questions, please mark an  in the one box that best describes 
your answer. 
1. In general, would you say your health is: 
 
Excellent Very good Good Fair Poor 
     
  1  2  3  4  5 
 








than one year 
ago 
About the 




than one year 
ago 
Much worse 
now than one 
year ago 
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3. The following questions are about activities you might do during a typical day.  
Does your health now limit you
  










    
 
 a  Vigorous activities
 heavy objects, participating in strenuous  
, such as running, lifting  
 sports  .................................................................... 1 .................. 2 ................. 3 
 
b   Moderate activities
  pushing a vacuum cleaner, bowling, or  
, such as moving a table,  
 playing golf ........................................................... 1 .................. 2 ................. 3 
 
c   Lifting or carrying groceries ................................ 1 .................. 2 ................. 3 
 
d  Climbing several
 
 flights of stairs .......................... 1 .................. 2 ................. 3 
e  Climbing one
 
 flight of stairs ................................. 1 .................. 2 ................. 3 
f  Bending, kneeling, or stooping ............................. 1 .................. 2 ................. 3 
 
g Walking more than a mile
 
 ..................................... 1 .................. 2 ................. 3        
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h Walking several hundred yards
 
 ............................. 1 .................. 2 ................. 3        
i Walking one hundred yards
 
 .................................... 1 .................. 2 ................. 3        
j  Bathing or dressing yourself ................................. 1 .................. 2 ................. 3        
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During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other regular daily activities as a result of your physical health
 
? 











      
a  Cut down on the amount of time
on work or other activities ....................................... 1 ........ 2 ........ 3......... 4 ........ 5 
 you spent  
b  Accomplished less
 
 than you would like ................. 1 ........ 2 ....... 3 ........ 4 ........ 5 
c  Were limited in the kind
    activities .................................................................. 1 ........ 2 ........ 3......... 4 ........ 5 
 of work or other  
d  Had difficulty
  activities (for example, it took extra effort)  ........... 1 ........ 2 ....... 3 ........ 4 ........ 5 
 performing the work or other  
 
4. During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of any emotional 
problems
 












      
a  Cut down on the amount of time
 on work or other activities ..................................... 1 ........ 2 ....... 3 ......... 4 ........ 5   
 you spent  
b  Accomplished less
 
 than you would like ............... 1 ........ 2 ....... 3 ......... 4 ........ 5  
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c  Did work or other activities 
 
less carefully  
than usual
 
 ............................................................... 1 ........ 2 ....... 3 ......... 4 ........ 5  
6. During the past 4 weeks, to what extent has your physical health or emotional 
problems
Not at all 
 interfered with your normal social activities with family, friends, neighbors, 
or groups? 
Slightly Moderately Quite a bit Extremely 
     
 1  2  3   4  5 
 
7. How much bodily pain have you had during the past 4 weeks
None 
? 
Very mild Mild Moderate Severe Very Severe 
      
 1  2  3  4  5  6 
 
8. During the past 4 weeks, how much did pain
Not at all 
 interfere with your normal work 
(including both work outside the home and housework)? 
A little bit Moderately Quite a bit Extremely 
     
 1  2  3  4  5 
 
 
    
83 
 
9. These questions are about how you feel and how things have been with you during the 
past 4 weeks.  For each question, please give the one answer that comes closest to the 














      
 
   id  f l f ll f lif ?  1 2     b  Have you been very nervous? ............................. 1 ......... 2 ......... 3 ......... 4 ......... 5  
 
c  Have you felt so down in the dumps  
 that nothing could cheer you up? ......................... 1 ......... 2 ......... 3 ......... 4 ......... 5  
d  Have you felt calm and peaceful? ....................... 1 ......... 2 ......... 3 ......... 4 ......... 5  
 e  Did you have a lot of energy? ............................. 1 ......... 2 ......... 3 ......... 4 ......... 5  
 f  Have you felt downhearted and  
 depressed? ............................................................ 1 ......... 2 ......... 3 ......... 4 ......... 5  
 
g  Did you feel worn out? ....................................... 1 ......... 2 ......... 3 ......... 4 ......... 5  
 h  Have you been happy? ........................................ 1 ......... 2 ......... 3 ......... 4 ......... 5  




10.  During the past 4 weeks, how much of the time has your physical health  or emotional 
problems
All of the 
 interfered with your social activities (like visiting friends, relatives, etc.)? 
Time 
Most of the 
time 
Some of the 
Time 
A little of the 
time 
None of the 
time 
     
    
84 
 
 1  2  3   4  5 
 
11.   How TRUE or FALSE is each
 











      
a  I seem to get sick a little easier  
than other people ........................... 1 ............ 2 ........... 3 ........... 4 ........... 5   
b  I am as healthy as anybody I know ....... 1 ........... 2 .......... 3 .......... 4 .......... 5 
c  I expect my health to get worse ............. 1 ........... 2 .......... 3 .......... 4 .......... 5  
d  My health is excellent............................ 1 ............ 2 ........... 3 ........... 4 ........... 5  
 
 






















Allergies (N = 120) 
   Range                    M (SD) 
Asthma (N = 120) 
      Range                   M (SD) 
Healthy (N = 120) 
      Range                M (SD) 
CES-D 0-49 15.50 (10.51) 0-50 13.92 (10.27) 0-47 11.24 (9.34) 
       
SAS 21-68 36.56 (9.67) 21-63 33.89 (8.41) 20-58 30.97 (6.81) 
       
SF-36 PCS 39.06-100 77.61 (17.15) 25.00-100.00 78.19 (15.99) 40.00-100.00 88.17 (9.60) 
       
SF-36 MCS 16.56-98.44 69.44 (19.05) 18.23-100.00 72.61 (17.27) 8.33-100.00 77.66 (14.88) 
       
Note. CES-D = Center for Epidemiologic Studies Depression Scale; SAS = Zung Self-Rating Anxiety Scale; SF-36 PCS = SF-36 
Health Survey Questionnaire Physical Component Summary Score; SF-36 MCS = SF-36 Health Survey Questionnaire Mental 




 1 2 3 4 5 6 
1. Age -- -.095 -.015 .009 -.058 -.100 
2. Sex  -- .227** .152** -.173** -.202** 
3. SAS   -- .794** -.727** -.597** 
4. CES-D    -- -.774** -.448** 
5. SF-36 MCS     -- .652** 
6. SF-36 PCS      -- 
 
Note. SAS = Zung Self-Rating Anxiety Scale; CES-D = Center for Epidemiologic 
Studies Depression Scale; SF-36 MCS = SF-36 Health Survey Questionnaire Mental 
Component Summary Score; SF-36 PCS = SF-36 Health Survey Questionnaire Physical 
Component Summary Score. ** p< .01. 
  











Allergies (N = 120) 
 
Number in 
Clinical Range (%) 
Asthma (N = 120) 
 
Number in 
Clinical Range (%) 
Healthy (N = 120) 
 
Number in 











     
SAS 45 26 (21.7) 13 (10.8) 4 (3.3) 
      
Note. CES-D = Center for Epidemiologic Studies Depression Scale; SAS = Zung Self-
Rating Anxiety Scale. 
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Scope and Method of Study: The purpose of the current study was to assess the 
relationships between depressive symptoms, anxious symptoms, and health-
related quality of life (HRQOL) in adolescents and young adults (AYAs) with 
allergies, asthma, and healthy controls.  Participants were undergraduate students 
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history of a chronic illness (N=120).  Participants completed a demographic form, 
the Center for Epidemiological Studies Depression Scale (CES-D), the Zung Self-
Rating Anxiety Scale (SAS), and the SF-36 Healthy Survey Questionnaire.  The 
participants were recruited from an online participant pool for undergraduate 
students.   
 
Findings and Conclusions:  The results revealed that both AYAs with allergies and 
asthma are experiencing poorer psychosocial functioning than their healthy peers.  
AYAs with allergies demonstrated higher levels of depressive symptoms than 
healthy AYAs, and AYAs with allergies demonstrated higher levels of anxious 
symptoms than AYAs with asthma and healthy AYAs. AYAs with asthma 
demonstrated higher levels of anxious symptoms than healthy AYAs.  Both 
AYAs with asthma and allergies demonstrated poorer physical HRQOL than 
healthy AYAs after controlling for anxious and depressive symptoms.  After 
controlling for anxious and depressive symptoms, the disease groups did not 
differ on mental HRQOL.  Overall, these results suggest that both AYAs with 
asthma and allergies are experiencing poorer psychosocial functioning, and 
although, often considered a relatively benign illness, allergies may be an 
important population to study within chronic illnesses.   
 
 
 
 
 
 
 
